Abstract Library

#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,

Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases

Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Blanco C, Crespo E, Gamo M, Villalobos L, Escribano P,

Keywords: TACE, TAE, GEP-NET,

#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms

Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,

Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,

#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain

Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Jimenez-Fonseca P, Custodio A, Lopez C, Carmona-Bayonas A,

Keywords: capecitabine, temozolomide,